超声与CT引导下碘-125粒子植入联合肝动脉化疗栓塞治疗肝切除术后复杂部位复发性肝细胞癌

Ultrasound and CT-guided implantation of iodine-125 seeds combined with transarterial chemoembolization for recurrent hepatocellular carcinoma at complex sites after hepatectomy.

作者信息

Wang Yeyan, Feng Jie

机构信息

Department of Ultrasound Medicine, The Second People's Hospital of China Three Gorges University, Yichang, Hubei, China.

Department of Radiology, The Second People's Hospital of China Three Gorges University, Yichang, Hubei, China.

出版信息

Brachytherapy. 2025 Mar-Apr;24(2):293-300. doi: 10.1016/j.brachy.2024.12.002. Epub 2025 Jan 24.

DOI:10.1016/j.brachy.2024.12.002

PMID:39863425

Abstract

OBJECTIVE

The objective of this study was to evaluate the efficacy and safety of TACE combined with 125I seeds (TACE-125I) in the treatment of recurrent HCC at complex sites after hepatectomy.

METHODS

This study retrospectively analyzed the clinical data of recurrent HCC patients located at complex sites (such as large blood vessels, diaphragm dome, etc.) after hepatectomy from January 2012 to December 2023, all of whom received TACE-125I or TACE therapy. Recur rence, overall survival (OS), progression-free survival (PFS) and complications were compared be tween the 2 groups.

RESULTS

A total of 152 patients with recurrent HCC were enrolled in this study, including 69 in the TACE-125I group and 83 in the TACE group. During follow-up, a total of 41 patients in the TACE-125I group experienced tumor recurrence, compared to 67 patients in the TACE group. The median OS in the TACE-125I group was 31 months, which was significantly higher than that in the TACE group (16 months, p < 0.001). Similarly, the median PFS was significantly higher in the TACE-125I group than in the TACE group.

CONCLUSIONS

Compared with TACE treatment, TACE-125I may be a more effective method for the treatment of recurrent HCC located at complex sites.

摘要

目的

本研究旨在评估经动脉化疗栓塞术（TACE）联合125I粒子（TACE-125I）治疗肝切除术后复杂部位复发性肝癌的疗效和安全性。

方法

本研究回顾性分析了2012年1月至2023年12月肝切除术后位于复杂部位（如大血管、膈顶等）的复发性肝癌患者的临床资料，所有患者均接受了TACE-125I或TACE治疗。比较两组患者的复发情况、总生存期（OS）、无进展生存期（PFS）和并发症。

结果

本研究共纳入152例复发性肝癌患者，其中TACE-125I组69例，TACE组83例。随访期间，TACE-125I组共有41例患者出现肿瘤复发，而TACE组为67例。TACE-125I组的中位OS为31个月，显著高于TACE组（16个月，p<0.001）。同样，TACE-125I组的中位PFS也显著高于TACE组。